/

PULM

Pulmatrix, Inc.Closed

1.38−0.05 −3.50%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.40

Prev close

1.43

Day range

1.361.42

52-week range

1.165.24

Volume

32.75K1.40×

Mkt cap

5.04M

P/E ttm

—

Fwd P/E

-0.31

EPS ttm

-1.10

Div yield

0.00%

Earnings

—

From 52w high

−73.64%

Price Chart

Yahoo Finance · delayed

PULMOct 13, 2026O 1.40H 1.42L 1.36C 1.38−0.05 (−3.50%)Vol 32.80K

SMA 501.52
SMA 2001.77

1Y change −71.84% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PULM Pulmatrix, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.50%
1 month: −2.13%
3 months: −14.81%
6 months: +10.84%
Year to date: −38.12%
1 year: −71.84%

Valuation & ownership

Market cap: 5.04M
Enterprise value: 3.84M
P/E (ttm): —
Forward P/E: -0.31
PEG ratio: —
Price / book: 3.17
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -1.10
EPS (forward): -4.50
Beta (5y monthly): 1.93
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 3.65M
Float: 3.65M
Short % of float: 1.35%
Short ratio (days): 1.10
Held by insiders: 0.78%
Held by institutions: 9.16%
Avg volume (3m): 23.31K
50-day average: 1.53
200-day average: 1.77
52-week change: −71.84%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 39.1
vs 50-day SMA: −9.48%
vs 200-day SMA: −21.82%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.48%
Realised vol (20d, ann.): 72.1%
From 52-week high: −73.64%
From 52-week low: +18.97%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Pulmatrix, Inc.

Yahoo Finance profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 2
Headquarters: Framingham, MA, United States
Website: pulmatrix.com
Officers: Mr. Peter Ludlum CMA, MBA Interim CEO & Interim CFO
Dr. Alexander M. Klibanov Ph.D. Founder

SEAS

Seasonality · PULM

2014–2026 · monthly returns

Strongest month Jan +30.98%Weakest month Dec −14.36%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	15.2	16.3	-56.9	-2.3	10.3	22.3	2.4	-15.5	3.4	-9.2			−38.1%
2025	10.3	4.9	-17.6	-0.8	35.9	-23.2	-18.4	-12.4	-1.4	1.4	-9.7	-49.9	−68.1%
2024	-7.0	15.0	-12.1	8.6	-1.6	3.2	12.4	-4.6	3.4	2.8	201.8	5.1	+275.3%
2023	3.9	-14.4	-15.4	0.7	-7.1	-1.8	-1.1	-11.3	-13.6	-6.9	9.0	-9.7	−52.1%
2022	-9.8	-21.8	10.5	-25.2	5.7	-15.0	-4.1	0.5	-19.2	-3.6	8.7	3.7	−55.7%
2021	18.5	9.2	-13.6	-28.6	-2.0	11.7	-18.7	-3.0	-2.4	8.7	-23.3	-34.3	−63.2%
2020	94.2	-4.2	-36.9	36.6	21.7	2.4	-23.3	-18.9	11.2	-5.9	23.2	-13.8	+38.4%
2019	-46.7	-18.8	22.1	-18.9	-1.0	-9.6	-5.6	1.7	-7.6	1.8	0.0	3.2	−64.2%
2018	28.4	-22.7	-63.6	-11.2	4.9	-5.1	2.2	-4.3	-15.9	1.1	-1.9	-34.6	−83.0%
2017	264.4	90.7	-14.9	-20.9	-8.0	-6.3	-4.2	-24.6	19.2	-14.6	-10.9	-9.6	+139.0%
2016	-32.2	0.1	2.8	13.3	-27.1	-19.0	8.2	-27.5	7.4	-22.4	-53.1	-1.7	−86.0%
2015	16.9	-5.3	-11.2	-2.6	18.5	-3.3	-29.2	-16.3	-13.7	-24.6	36.2	-16.7	−52.0%
2014				0.1	-7.3	-5.7	-9.7	-3.9	-6.9	-12.0	-4.2	-14.2	−48.8%

13F

Investors Holding PULM

latest 13F filings of 29 followed managers

Investors holding PULM
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$208.6K	0.00%	122.70K	+12%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PULM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PULM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Pulmatrix, Inc.

Seasonality · PULM

Insider Activity · PULM

Congress Trades · PULM

Investors Holding PULM

Investors Holding PULM

Congress Trades · PULM

Insider Activity · PULM

Seasonality · PULM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Pulmatrix, Inc.

Earnings & Dividends

News